Implication of embB gene mutation in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis

Young Kil Park, Sonya Shin, Sang Jae Kim, Won Jung Koh, O. Jung Kwon, Bum Jun Kim, Yoon Ho Kook, Sangnae Cho, Woo Jin Lew, Gill Han Bai

Research output: Contribution to journalArticle

Abstract

Background: Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether these mutations are associated with EMB resistance Methods: The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products were purified and directly sequenced. We reviewed the history of past drug susceptibility test results. Results: Out of 36 EMB-susceptible strains, 3 strains (8.3%) had a mutation in codon 306 or 406 of the embB gene. These three strains had at least isoniazid resistance. They grew at 1.0 meg/ml of EMB in Lowenstein-Jensen media. The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain had been EMB-resistant in past drug susceptibility tests. Conclusion: EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test not by itself.

Original languageEnglish
Pages (from-to)266-271
Number of pages6
JournalTuberculosis and Respiratory Diseases
Volume59
Issue number3
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

Ethambutol
Mycobacterium tuberculosis
Mutation
Genes
Pharmaceutical Preparations
Isoniazid
Point Mutation
Codon
Tuberculosis
History
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Park, Young Kil ; Shin, Sonya ; Kim, Sang Jae ; Koh, Won Jung ; Kwon, O. Jung ; Kim, Bum Jun ; Kook, Yoon Ho ; Cho, Sangnae ; Lew, Woo Jin ; Bai, Gill Han. / Implication of embB gene mutation in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. In: Tuberculosis and Respiratory Diseases. 2005 ; Vol. 59, No. 3. pp. 266-271.
@article{f18bc3360b9f46dd8f6d5696b7aa3389,
title = "Implication of embB gene mutation in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis",
abstract = "Background: Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether these mutations are associated with EMB resistance Methods: The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products were purified and directly sequenced. We reviewed the history of past drug susceptibility test results. Results: Out of 36 EMB-susceptible strains, 3 strains (8.3{\%}) had a mutation in codon 306 or 406 of the embB gene. These three strains had at least isoniazid resistance. They grew at 1.0 meg/ml of EMB in Lowenstein-Jensen media. The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain had been EMB-resistant in past drug susceptibility tests. Conclusion: EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test not by itself.",
author = "Park, {Young Kil} and Sonya Shin and Kim, {Sang Jae} and Koh, {Won Jung} and Kwon, {O. Jung} and Kim, {Bum Jun} and Kook, {Yoon Ho} and Sangnae Cho and Lew, {Woo Jin} and Bai, {Gill Han}",
year = "2005",
month = "1",
day = "1",
doi = "10.4046/trd.2005.59.3.266",
language = "English",
volume = "59",
pages = "266--271",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "3",

}

Implication of embB gene mutation in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. / Park, Young Kil; Shin, Sonya; Kim, Sang Jae; Koh, Won Jung; Kwon, O. Jung; Kim, Bum Jun; Kook, Yoon Ho; Cho, Sangnae; Lew, Woo Jin; Bai, Gill Han.

In: Tuberculosis and Respiratory Diseases, Vol. 59, No. 3, 01.01.2005, p. 266-271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Implication of embB gene mutation in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis

AU - Park, Young Kil

AU - Shin, Sonya

AU - Kim, Sang Jae

AU - Koh, Won Jung

AU - Kwon, O. Jung

AU - Kim, Bum Jun

AU - Kook, Yoon Ho

AU - Cho, Sangnae

AU - Lew, Woo Jin

AU - Bai, Gill Han

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether these mutations are associated with EMB resistance Methods: The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products were purified and directly sequenced. We reviewed the history of past drug susceptibility test results. Results: Out of 36 EMB-susceptible strains, 3 strains (8.3%) had a mutation in codon 306 or 406 of the embB gene. These three strains had at least isoniazid resistance. They grew at 1.0 meg/ml of EMB in Lowenstein-Jensen media. The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain had been EMB-resistant in past drug susceptibility tests. Conclusion: EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test not by itself.

AB - Background: Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether these mutations are associated with EMB resistance Methods: The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products were purified and directly sequenced. We reviewed the history of past drug susceptibility test results. Results: Out of 36 EMB-susceptible strains, 3 strains (8.3%) had a mutation in codon 306 or 406 of the embB gene. These three strains had at least isoniazid resistance. They grew at 1.0 meg/ml of EMB in Lowenstein-Jensen media. The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain had been EMB-resistant in past drug susceptibility tests. Conclusion: EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test not by itself.

UR - http://www.scopus.com/inward/record.url?scp=26944496837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944496837&partnerID=8YFLogxK

U2 - 10.4046/trd.2005.59.3.266

DO - 10.4046/trd.2005.59.3.266

M3 - Article

AN - SCOPUS:26944496837

VL - 59

SP - 266

EP - 271

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 3

ER -